University of California San Francisco

Biography

Andrew H. Ko, M.D. specializes in the treatment of malignancies of the gastrointestinal tract, including esophageal, stomach, colorectal, pancreatic, and hepatobiliary cancers. Dr. Ko graduated magna cum laude from Brown University and received his medical degree from Johns Hopkins School of Medicine. After an internship and residency at Beth Israel Hospital in Boston, he completed a fellowship in medical oncology at Stanford University before joining the UCSF faculty in 2001.

Dr. Ko regularly presents patient cases at the Thoracic Oncology and GI Tumor Boards. He is a frequent lecturer in the GI cancer field and has served as Principal Investigator for trials using novel agents in esophageal and GI cancers. Dr. Ko holds memberships in numerous professional organizations and is a member of the Protocol Review and Data and Safety Monitoring committees at UCSF.

Education

Education
  • Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
  • Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Residencies
  • 1995-1996, Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
  • 1996-1998, Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
Fellowships
  • 1998-2001, Stanford University School of Medicine, fellow, Division of Medical Oncology

Board Certifications

  • American Board of Internal Medicine: Internal Medicine, Medical Oncology

Clinical Expertise

Barrett's Esophagus
Cholangiocarcinoma
Colon Cancer
Esophageal Cancer
Gall Bladder Cancer
Hepatocellular Carcinoma (Liver Cancer)
Lynch Syndrome
Neuroendocrine Tumors
Pancreatic Cancer
Rectal Cancer
Small Intestine Cancer
Stomach Cancer

Program Affiliations

  • Department of Medicine, Division of Hematology Oncology
  • Thoracic Oncology Program\
  • Member, UCSF Comprehensive Cancer Center

Research Interests

  • Esophageal cancer
  • Pancreatic cancer
  • Signal transduction pathways in gastrointestinal development
  • Targeted therapies